Inpharma 1590 - 2 Jun 2007

Desvenlafaxine cools downmenopausal vasomotor symptoms

Desvenlafaxine [Pristiq]* has shown potential in thetreatment of moderate-to-severe vasomotor symptoms(hot flashes and night sweats) associated withmenopause, according to the results of threerandomised, multicentre phase III studies presented atthe Annual Clinical Meeting of the American College ofObstetricians and Gynecologists

These studies involved postmenopausal women with≥ 50 moderate-to-severe hot flashes per week. One1-year study involved 689 such women who receiveddesvenlafaxine at a variety of multiple doses, or placebo.Several desvenlafaxine doses were associated withreductions in the number and severity of hot flashes andnight sweats, at weeks 4 and 12, with an onset oftreatment effect within 1 week of therapy initiation.

A 6-month study involved 541 women who receiveddesvenlafaxine or placebo. Compared with placebo,desvenlafaxine was associated with significantimprovements in all primary endpoints, includingsignificant reductions in the number of hot flashesthroughout the study (between –60% and –66%).

A 12-week study included 451 women who receiveddesvenlafaxine, tibolone or placebo. All treatmentgroups had decreases from baseline in the number andseverity of hot flashes; however, while the decrease wassignificantly greater in the tibolone group than in theplacebo group, there was no significant differencebetween the desvenlafaxine and placebo groups.* Wyeth; preregistration for menopausal syndrome in the US andEurope, and for depression in the US

Wyeth Pharmaceuticals. Wyeth Presents Phase 3 Data for Pristiq, anInvestigational Non-Hormonal Therapy for Menopausal Hot Flashes and NightSweats. Media Release : 9 May 2007. Available from: URL: http://www.wyeth.com 809075564

1

Inpharma 2 Jun 2007 No. 15901173-8324/10/1590-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved